Refine my results

Is there a role for dual PI3K/mTOR inhibitors for patients affected with lymphoma?

Tarantelli, Chiara ; Lupia, Antonio ; Stathis, Anastasios ; Bertoni, Francesco

In: International journal of molecular sciences, 2020, vol. 21, no. 3, p. 21 p

The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti- cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K/mTOR inhibitors as single agents and in combination in lymphomas. Clinical...